BidaskClub Lowers Ironwood Pharmaceuticals (NASDAQ:IRWD) to Strong Sell

BidaskClub lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a sell rating to a strong sell rating in a report issued on Wednesday, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. ValuEngine raised Ironwood Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, August 1st. Mizuho set a $20.00 price target on Ironwood Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, May 2nd. Morgan Stanley set a $13.00 price target on Ironwood Pharmaceuticals and gave the stock a hold rating in a research note on Friday, May 3rd. HC Wainwright set a $13.00 price target on Ironwood Pharmaceuticals and gave the stock a hold rating in a research note on Monday, June 24th. Finally, Wedbush upped their price target on Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock a neutral rating in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $15.15.

Shares of IRWD stock opened at $8.72 on Wednesday. The business’s fifty day moving average is $10.03 and its 200 day moving average is $11.68. Ironwood Pharmaceuticals has a twelve month low of $8.69 and a twelve month high of $19.64.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.15. The firm had revenue of $102.22 million during the quarter, compared to analysts’ expectations of $89.28 million. Ironwood Pharmaceuticals’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.22) earnings per share. As a group, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.01 earnings per share for the current fiscal year.

In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 20,000 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $10.00, for a total value of $200,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 21,712 shares of company stock worth $218,806 over the last three months. Corporate insiders own 5.90% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 15,606,157 shares of the biotechnology company’s stock valued at $170,730,000 after purchasing an additional 664,893 shares in the last quarter. Brown Capital Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 19.4% during the second quarter. Brown Capital Management LLC now owns 12,329,890 shares of the biotechnology company’s stock valued at $134,889,000 after purchasing an additional 2,003,252 shares in the last quarter. Janus Henderson Group PLC increased its position in Ironwood Pharmaceuticals by 12.8% during the second quarter. Janus Henderson Group PLC now owns 7,505,293 shares of the biotechnology company’s stock valued at $82,108,000 after acquiring an additional 852,356 shares during the last quarter. EcoR1 Capital LLC increased its position in Ironwood Pharmaceuticals by 6.2% during the second quarter. EcoR1 Capital LLC now owns 4,671,408 shares of the biotechnology company’s stock valued at $51,105,000 after acquiring an additional 274,240 shares during the last quarter. Finally, Westfield Capital Management Co. LP increased its position in Ironwood Pharmaceuticals by 27.1% during the second quarter. Westfield Capital Management Co. LP now owns 2,392,774 shares of the biotechnology company’s stock valued at $26,177,000 after acquiring an additional 510,900 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

See Also: Moving Average (MA)

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.